1433280-18-2

Upstream product

• 1373164-85-2 (2S,4S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-4-methylsulfanyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 188109-89-9 (2S,4S)-4-methylsulfanyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 72-18-4 L-valine 

Downstream Products

• 1433280-40-0 4'-{2-[(2S,4S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-4-methylsulfanyl-pyrrolidin-2-yl]-1H-imidazol-4-yl}-2-trifluoromethoxy-biphenyl-4-carboxylic acid methyl ester 
• 1433280-21-7 4'-{2-[(2S,4S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-4-methylsulfanyl-pyrrolidin-2-yl]-1H-imidazol-4-yl}-2-trifluoromethoxy-biphenyl-4-carboxylic acid trifluoroacetic acid salt 
• 1433280-19-3 [(S)-2-methyl-1-((2S,4S)-4-methylsulfanyl-2-{4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]-carbamic acid methyl ester 

Relevant academic research and scientific papers

HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.